Shuqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuqi Wang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Eric Kam-Pui Lee
Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
4 shared publications - Jaeil Ahn
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University , Washington, DC
3 shared publications - Benjamin Hon Kei Yip
JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China
2 shared publications - Richard J. McManus
Dean’s Office, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, UK
2 shared publications - Samuel Yeung-Shan Wong
The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
2 shared publications - Abigail Dove
Care Sciences and Society, Karolinska institutet
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (12) , 1694-1706
Effectiveness of care delivery models for knee osteoarthritis in primary healthcare settings: A systematic review and meta-analysis of randomized controlled trials
- 4 September 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (12) , 1694-1706
Open AccessEffectiveness of care delivery models for knee osteoarthritis in primary healthcare settings: A systematic review and meta-analysis of randomized controlled trials
- Open Access
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e34
Feasibility and preliminary effectiveness of mindfulness-based stress reduction program on patients with nocturnal hypertension: a pilot randomized controlled trial
Wang S, et al. Clin Hypertens. 2026 ;32(1):e34. https://doi.org/10.5646/ch.2026.32.e34
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e34
Open AccessFeasibility and preliminary effectiveness of mindfulness-based stress reduction program on patients with nocturnal hypertension: a pilot randomized controlled trial
Wang S, et al. Clin Hypertens. 2026 ;32(1):e34. https://doi.org/10.5646/ch.2026.32.e34
- Open Access
- 25 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112344
The utility of common predictive models for detecting undiagnosed diabetes and prediabetes defined by HbA1c in a Chinese population
- 25 June 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 226, 112344
Open AccessThe utility of common predictive models for detecting undiagnosed diabetes and prediabetes defined by HbA1c in a Chinese population
- Open Access
- 23 May 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (14) , 1335-1343
Developing and validating a diagnostic threshold for central blood pressure in assessing cardiovascular risks
Aims: This study aimed to establish an outcome-derived threshold for central blood pressure (cBP) and evaluate its clinical utility in stratifying cardiovascular (CVD) risk. Methods and results: A retrospective cohort study of 34 289 adults without prior CVD was conducted using the UK Biobank dataset. The primary endpoint was a composite of cardiovascular mortality and non-fatal cardiovascular events. Diagnostic threshold for cBP was developed by bootstrap and approximation methods, based on the current brachial BP. Cox regression models were employed to evaluate the clinical utility of diagnostic thresholds for cBP in predicting in CVD. A diagnostic threshold of 135 mmHg for central systolic blood pressure (SBP) corresponded to the threshold of 140 mmHg for brachial SBP. Simultaneous assessment of brachial and central SBP configurated following categories: brachial and central normotension (49.84%), isolated brachial hypertension (2.23%), isolated central hypertension (3.65%) and concordant brachial and central hypertension (44.28%). Compared with concordant normotension, hazard ratios for cardiovascular events were 0.81 (0.45, 1.44) for isolated brachial hypertension, 1.70 (1.23, 2.35) for isolated central hypertension and 1.51 (1.30, 1.76) for concordant hypertension. The inclusion of cBP improved model fit and discrimination for predicting CVD beyond brachial BP alone. Conclusion: This study established a diagnostic threshold of 135 mmHg for central SBP. Individuals with central HT exhibited elevated risks of CVD, regardless of brachial HT status. Incorporating central BP enhanced the prediction of CVD risk beyond traditional BP measurement alone.
- 23 May 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (14) , 1335-1343
Open AccessDeveloping and validating a diagnostic threshold for central blood pressure in assessing cardiovascular risks
Aims: This study aimed to establish an outcome-derived threshold for central blood pressure (cBP) and evaluate its clinical utility in stratifying cardiovascular (CVD) risk. Methods and results: A retrospective cohort study of 34 289 adults without prior CVD was conducted using the UK Biobank dataset. The primary endpoint was a composite of cardiovascular mortality and non-fatal cardiovascular events. Diagnostic threshold for cBP was developed by bootstrap and approximation methods, based on the current brachial BP. Cox regression models were employed to evaluate the clinical utility of diagnostic thresholds for cBP in predicting in CVD. A diagnostic threshold of 135 mmHg for central systolic blood pressure (SBP) corresponded to the threshold of 140 mmHg for brachial SBP. Simultaneous assessment of brachial and central SBP configurated following categories: brachial and central normotension (49.84%), isolated brachial hypertension (2.23%), isolated central hypertension (3.65%) and concordant brachial and central hypertension (44.28%). Compared with concordant normotension, hazard ratios for cardiovascular events were 0.81 (0.45, 1.44) for isolated brachial hypertension, 1.70 (1.23, 2.35) for isolated central hypertension and 1.51 (1.30, 1.76) for concordant hypertension. The inclusion of cBP improved model fit and discrimination for predicting CVD beyond brachial BP alone. Conclusion: This study established a diagnostic threshold of 135 mmHg for central SBP. Individuals with central HT exhibited elevated risks of CVD, regardless of brachial HT status. Incorporating central BP enhanced the prediction of CVD risk beyond traditional BP measurement alone.
- Open Access
- 14 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2463435
Home blood pressure during night-time sleep – a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled trial
This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.
- 14 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2463435
Open AccessHome blood pressure during night-time sleep – a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled trial
This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S8)
Association of kidney function with dementia and brain pathologies: A community‐based cohort study
Background: Kidney function has been linked to cognitive function, but its relation to dementia and mechanisms underlying this relation remains unclear. We aimed to examine the association of impaired kidney function with dementia and brain pathologies.Method: Within Rush Memory and Aging Project, 1380 dementia‐free subjects (75.22% female; mean age: 79.42±7.61 years) at baseline were followed for up to 22 years. Blood samples were taken at baseline and serum creatinine was measured to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula. Kidney function dichotomized as normal (eGFR ≥ 60 mL/min/1.73 m2) or impaired (eGFR 2). Dementia, including Alzheimer’s dementia, was diagnosed following international criteria. During the follow‐up, 469 participants died and underwent autopsies for neuropathological assessment (including Alzheimer’s disease [AD], vascular, and other brain pathologies). Data were analyzed using Cox regression, Laplace regression, and logistic regression.Result: At baseline, 895 (64.86%) participants with normal kidney function and 485 (35.14%) with impaired. Over follow‐up (median [interquartile range]: 5 [2–9] years), 300 (21.74%) participants developed dementia, including 273 (19.78%) with Alzheimer’s dementia. In multi‐adjusted Cox regression, lower eGFR was does‐dependently associated with higher dementia risk (hazard ratio [HR] = 1.01, 95% confidence interval [CI]: 1.01–1.02, P = 0.003) and Alzheimer’s dementia risk (HR = 1.01, 95% CI: 1.00‐1.02, P = 0.002). Compared to normal kidney function, impaired kidney function was associated with a greater risk of dementia (HR = 1.49, 95% CI: 1.16–1.91) and Alzheimer’s dementia (HR = 1.45, 95% CI: 1.12–1.89). The median time to the development of dementia or Alzheimer’s dementia was 2.48 (95% CI: 0.36–3.03) or 2.56 (95% CI: 0.37–2.79) years shorter in people with impaired vs. normal kidney function, respectively. In brain pathology analysis, impaired kidney function was significantly related to higher burdens of cerebral amyloid angiopathy (odds ratio = 2.03, 95% CI: 1.23–3.35).Conclusion: Impaired kidney function is associated with an increased risk of dementia and Alzheimer’s dementia. Vascular mechanisms may underlie this association.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S8)
Open AccessAssociation of kidney function with dementia and brain pathologies: A community‐based cohort study
Background: Kidney function has been linked to cognitive function, but its relation to dementia and mechanisms underlying this relation remains unclear. We aimed to examine the association of impaired kidney function with dementia and brain pathologies.Method: Within Rush Memory and Aging Project, 1380 dementia‐free subjects (75.22% female; mean age: 79.42±7.61 years) at baseline were followed for up to 22 years. Blood samples were taken at baseline and serum creatinine was measured to calculate estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula. Kidney function dichotomized as normal (eGFR ≥ 60 mL/min/1.73 m2) or impaired (eGFR 2). Dementia, including Alzheimer’s dementia, was diagnosed following international criteria. During the follow‐up, 469 participants died and underwent autopsies for neuropathological assessment (including Alzheimer’s disease [AD], vascular, and other brain pathologies). Data were analyzed using Cox regression, Laplace regression, and logistic regression.Result: At baseline, 895 (64.86%) participants with normal kidney function and 485 (35.14%) with impaired. Over follow‐up (median [interquartile range]: 5 [2–9] years), 300 (21.74%) participants developed dementia, including 273 (19.78%) with Alzheimer’s dementia. In multi‐adjusted Cox regression, lower eGFR was does‐dependently associated with higher dementia risk (hazard ratio [HR] = 1.01, 95% confidence interval [CI]: 1.01–1.02, P = 0.003) and Alzheimer’s dementia risk (HR = 1.01, 95% CI: 1.00‐1.02, P = 0.002). Compared to normal kidney function, impaired kidney function was associated with a greater risk of dementia (HR = 1.49, 95% CI: 1.16–1.91) and Alzheimer’s dementia (HR = 1.45, 95% CI: 1.12–1.89). The median time to the development of dementia or Alzheimer’s dementia was 2.48 (95% CI: 0.36–3.03) or 2.56 (95% CI: 0.37–2.79) years shorter in people with impaired vs. normal kidney function, respectively. In brain pathology analysis, impaired kidney function was significantly related to higher burdens of cerebral amyloid angiopathy (odds ratio = 2.03, 95% CI: 1.23–3.35).Conclusion: Impaired kidney function is associated with an increased risk of dementia and Alzheimer’s dementia. Vascular mechanisms may underlie this association.
- 1 January 2022
- Published by International Press of Boston in Statistics and Its Interface
- Vol. 15 (2) , 181-196
Stochastic functional linear models for gene-based association analysis of quantitative traits in longitudinal studies
International Press of Boston - publishers of scholarly mathematical and scientific journals and books
- 1 January 2022
- Published by International Press of Boston in Statistics and Its Interface
- Vol. 15 (2) , 181-196
Stochastic functional linear models for gene-based association analysis of quantitative traits in longitudinal studies
International Press of Boston - publishers of scholarly mathematical and scientific journals and books
- 9 September 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (5) , 697-706
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia
Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment‐related complications, as well as short‐term mortality and overall survival (OS) in 756 newly diagnosed AML patients. We conducted a retrospective multicenter study to examine treatment‐related complications and OS according to pretreatment serum albumin levels: normal albumin ≥3.5 g/dl, marked hypoalbuminemia p < 0.01). Similarly, 60‐day mortality rate was significantly higher in the hypoalbuminemia group (24.0%) and marked hypoalbuminemia group (45%) compared with normal albumin group (8.3%; p < 0.01). Patients with lower baseline albumin levels have increased treatment‐related morbidity and mortality, suggesting that pre‐treatment serum albumin is an important independent prognostic marker.
- 9 September 2021
- Published by Wiley in Hematological Oncology
- Vol. 39 (5) , 697-706
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia
Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment‐related complications, as well as short‐term mortality and overall survival (OS) in 756 newly diagnosed AML patients. We conducted a retrospective multicenter study to examine treatment‐related complications and OS according to pretreatment serum albumin levels: normal albumin ≥3.5 g/dl, marked hypoalbuminemia p < 0.01). Similarly, 60‐day mortality rate was significantly higher in the hypoalbuminemia group (24.0%) and marked hypoalbuminemia group (45%) compared with normal albumin group (8.3%; p < 0.01). Patients with lower baseline albumin levels have increased treatment‐related morbidity and mortality, suggesting that pre‐treatment serum albumin is an important independent prognostic marker.
- Open Access
- 25 August 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (11) , E430-E433
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
- 25 August 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (11) , E430-E433
Open AccessPembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
- Open Access
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (11) , e1914531
Publication Rate and Characteristics of Lung Cancer Clinical Trials
Clinical trials play a crucial role in shaping the practice of medicine. Nonreporting of clinical trial results affects the validity of the literature and can negatively affect patient care. Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.1 Studies assessing reporting of clinical trial results in thoracic oncology are lacking. We sought to investigate the publication rate among registered lung cancer clinical trials.
- 1 November 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (11) , e1914531
Open AccessPublication Rate and Characteristics of Lung Cancer Clinical Trials
Clinical trials play a crucial role in shaping the practice of medicine. Nonreporting of clinical trial results affects the validity of the literature and can negatively affect patient care. Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.1 Studies assessing reporting of clinical trial results in thoracic oncology are lacking. We sought to investigate the publication rate among registered lung cancer clinical trials.